Adverse reactions of atezolizumab versus durvalumab based on OpenFDA

Abstract

Objective To analyze the adverse drug reactions (ADR) of atezolizumab and durvalumab based on the US Food and Drug Administration Public Data Open Project (OpenFDA) to provide reference for rational clinical use of drugs. Methods The ADR data of atezolizumab and durvalumab from January 1, 2004 to January 28, 2022 were retrieved through the application programming interface (API) access to the interactive icon panel of the OpenFDA ADR endpoint. Results A total of 13 630 and 5 374 ADR reports respectively related to atezolizumab and durvalumab were obtained. More cases were reported in males than in females. The most common ADR of atezolizumab were fever, diarrhea and pneumonia, and the common ADR of durvalizumab was radiation pneumonitis. The incidences of ADR and serious ADR were similar in atezolizumab and durvalumab, except the incidences of anemia, febrile neutropenia and radiation pneumonitis. Conclusion ADR of atezolizumab and durvalizumab can be quickly and conveniently excavated and studied based on the OpenFDA database. With the increase of the use of these two drugs, the rare ADR in clinic is increasingly prominent, so clinical medication monitoring should be strengthened to promote their safe use.

Keywords

• atezolizumab
• durvalumab
• us food and drug administration public data open project
• programmed cell death ligand 1 inhibitor
• adverse reaction